Summary
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins. The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy. The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems by offering a 25-fold yield increase and a 10-fold cost reduction. Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity as plants are well known to be the most promising system for production upscaling.
Core Biogenesis’s ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Core Biogenesis’s ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190139157 |
| Start date: | 01-01-2023 |
| End date: | 31-12-2024 |
| Total budget - Public funding: | 1 647 700,00 Euro - 1 153 390,00 Euro |
Cordis data
Original description
Core Biogenesis uses plant-based expression systems for the very large-scale and high-quality bioproduction of pharmaceutical-grade recombinant proteins. The latter are used as growth factors (GF) in synthetic cell culture media for clinical and commercial scale biomanufacturing of cell therapy. The company has developed a novel advanced proprietary bioprocess integrating breakthrough innovations overcoming major technical issues of plant systems by offering a 25-fold yield increase and a 10-fold cost reduction. Its biomanufacturing platform will enable Core Biogenesis to fully exploit the great potential of plants for large and scalable production capacity as plants are well known to be the most promising system for production upscaling.Core Biogenesis’s ambition is to position itself as the European leader in plant-based biomanufacturing by 2025.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
